

CustomVis plc

("CustomVis", "the Group" or "the Company")

Final Results for the year ended 30 June 2007

CustomVis develops, manufactures and sells laser systems for refractive surgery of the eye. The Directors believe it is currently the only company in the world marketing a solid state laser to perform this surgery. Solid state is widely accepted as the next generation technology for this industry and has the potential to eventually replace all the gas excimer lasers currently used for this purpose.

HIGHLIGHTS

- Revenue increased 888 per cent. to £880,613 (2006 restated: £89,088)
- Loss before tax reduced by 49 per cent. to £1.44 million (2006 restated: £2.16 million)
- Production increased to three lasers per month inline with strategy
- Installed nine lasers in the year ended 30 June 2007
- Over 20,000 eyes have now been operated on
- A further 10 lasers have been sold since 1 July 2007, with firm orders for four more by end November 2007
- New developments include multi-purpose laser, retinal imaging device and procedure for presbyopia (long-sight)

Paul van Saarloos, CEO of CustomVis, commented, "With an installed base of 19 lasers around the world, we are confident that this number will rise substantially during 2008, as the industry moves to embrace Solid State technology. Our laser, with its leading eye tracking technology and laser controlled parameters, has the potential to out-perform excimer lasers in terms of clinical results."

For Further information, please contact:

CustomVis plc

Paul van Saarloos, CEO +61 410 497 456

John East & Partners Limited

David Worlidge 020 7628 2200

Conduit PR

Christian Taylor-Wilkinson 020 7429 6609

CHAIRMAN'S STATEMENT

INTRODUCTION

CustomVis develops, manufactures and sells laser systems for refractive surgery of the eye. It is currently the only company in the world marketing a solid state laser to perform this surgery. Solid state is widely accepted as the next generation technology for this industry and has the potential to eventually replace all the gas excimer lasers currently used for this purpose.

The CustomVis laser also has the most advanced eye tracking system in the industry, capable of tracking more types of eye movements with better accuracy and substantially higher response speeds compared with current excimer lasers. The Company's laser is the only system designed from the ground up for customised surgery, which in turn optimises the result for each eye. It is capable of correcting myopia, astigmatism and hyperopia. In addition, development work is being conducted to use the laser to correct presbyopia. The laser is currently in use in 12 countries and over a thousand eyes are treated with this new technology every month.

The CustomVis Pulzar Z1 is a solid state refractive laser. The excimer lasers in use today use fluorine gas, which is toxic, degrades quickly causing fluctuations in energy, and is increasingly difficult to ship and store. It is the Company's belief that a move away from the use of fluorine gas will become a key selling point with surgeons.

Solid state provides a far more reliable laser that is much simpler to use. It can be quickly turned on at any time with virtually no cost. With fast start up times, consistent energy levels, lower running costs and faster overall treatment times, the Directors believe that solid state is a commercially superior laser for performing refractive surgery. In addition, the results from the Company's laser are not affected by the hydration state of the corneal tissue and it does less thermal damage, and consequently the Directors believe the solid state wavelength is also more suitable for refractive surgery.

Clinical results from the CustomVis laser are consistent with those of the excimer laser and have been well received by surgeons. With leading eye tracking and laser control parameters the CustomVis laser has the potential to out-perform the excimer lasers in terms of clinical results. It is the Directors' view that this potential will be reached as further experience is gained with solid state technology.

#### OVERVIEW OF THE TRADING YEAR

The Group made a loss for the year of £1,438,318 (2006: £2,159,919) after recognising a charge of £107,860 (2006: £3,543) arising as a result of the requirement to adopt Financial Reporting Standard 20: Share-based payments ("FRS 20") on turnover of £880,613 (2006: £89,088).

The 2006/07 financial year has seen the Company make significant progress. In June 2006, just before the start of the financial year this report covers, the Company re-launched the Pulzar Z1 laser. Progress to date includes the installation of 20 lasers, the treatment of approximately 20,000 eyes and an established sales order flow. In recent months, the Company's production capability has been shown to be in excess of three lasers per month.

During the year under review the Company raised £1,383,646 (net of issue expenses) via a placing of 30,500,000 ordinary shares at 5p per share to fund ongoing operations and growth. The net cash outflow from operating activities during 2006/07 decreased to £1,706,887 compared to £2,287,355 in the corresponding year. The Directors are confident that they will be able to fund ongoing operations and growth through existing and prospective sales and other options the Board is currently pursuing.

The recent focus of the Directors has been on increasing production to three lasers per month and to devote more time and attention to the sales and marketing effort. Since 1 July 2007 the Company has made 10 firm sales. The Company has yet to achieve its internal sales target of selling three lasers a month due to the intense competitive pressures in the marketplace. However the Directors remain confident that based on the current sales pipeline they are optimistic of achieving this target for the remainder of 2007/08.

During the course of the audit of the financial statements for the year ended 30 June 2007 the Company was advised that certain sales of lasers which had previously been classified as leased sales in the Company's books, should be classified as outright sales. The interim results for the six months ended 31 December 2006 did not recognise income on this basis. Accordingly, the Directors have re-issued the interim results for the six months ended 31 December 2006 to reflect the correct accounting treatment.

In addition, we have adopted FRS 20 ("share based payments") which requires the determination of "fair value" of all employee options and share based payments and for this value to be recognised as an expense in the financial statements. The impact of this change is detailed in Note 25.

## SALES AND MARKETING

In the year ended 30 June 2007, CustomVis installed nine lasers. These sales being based on receipt by the Company of a deposit and regular payments over a fixed term, typically two years.

There are significant barriers for companies wishing to enter the laser refractive surgery market. Most of the Company's competitors are large multinational companies who are currently spending large sums of money marketing their lasers.

The lasers are high value products which are typically purchased by individual doctors. To date, doctors have tended to purchase lasers from large companies as they are more confident those companies will be better placed to service their needs during the expected useful life of the device.

The vast majority of eyes undergoing surgery using these devices are considered to be normally sighted eyes and to date excimer lasers have demonstrated reliable and consistent results. As a result, surgeons are naturally very nervous about trying new technology until it has been fully proven.

The aggressive marketing of our competitors is increasingly being directed at CustomVis. However, our growing installed base now provides evidence against claims made by our competitors that solid state does not work as effectively as excimer lasers. The Directors believe the aggressive negative marketing effort by our competitors is the strongest indication that the Company is starting to threaten the market share of those companies.

CustomVis continues to demonstrate its lasers at the world's major ophthalmic conferences and the feedback to date has been very positive. In addition, it has taken a more direct approach to some markets, providing strong clinical, technical and experienced sales support. This approach has been successful and has allowed the Company to establish a sales order flow into a limited number of countries. We intend to continue this approach in order to expand into new regions.

## PRODUCTION

In recent months the CustomVis production department has been working hard to demonstrate it is able to manufacture a minimum of three Pulzar Z1 laser systems per month in order to meet what the Directors believe will be the short term future demand for the product.

The production facility has been expanded and improved to handle the storage and assembly requirements of the increased manufacturing activity.

CustomVis has recruited additional skilled production personnel in the period to ensure that manufacturing deadlines are met and that stringent quality controls are maintained. All components are thoroughly inspected and tested prior to installation in one of our laser systems.

CustomVis' engineers are dedicated to performing intensive test programs on every Pulzar Z1 refractive laser to ensure the products leaving the factory are accurate, safe and reliable products.

## RESEARCH AND DEVELOPMENT

Research and development remains a key element of CustomVis. This work can be divided into three main areas; reducing the cost of production, developing new products and adding new treatment parameters to the Pulzar Z1 laser.

CustomVis is currently six months into a two year project focused upon significantly reducing the cost of production of the Pulzar Z1. The Directors are pleased with progress to date and are confident that they will be able to reduce the cost of manufacture of the Company's laser such that it will have a significant cost of goods advantage over the excimer laser products in the marketplace.

In the period under review the Company has been awarded a significant R&D grant from the Australian Federal Government to develop a multipurpose laser. This

project is expected to lead to the development of a new laser system that is not only an enhanced refractive laser, but will also take advantage of the solid state nature of the laser to allow ophthalmologists to perform types of treatments excimer lasers are not currently capable of performing. The multi-purpose nature of this laser is expected to encourage those ophthalmologists who would not otherwise have made the capital investment to enter this market.

CustomVis is also working on a low cost retinal imaging device that is expected to be launched in the current financial year. Preliminary market research conducted by our distributors suggests this device has the potential to generate significant revenues within the next three years. The Company also has other products under development, which are expected to be launched in the short to medium term.

The new treatment parameter for the Pulzar Z1 laser that is generating particular interest is a treatment for people with Presbyopia. Presbyopia becomes an issue for practically all people as they age. For most, this condition occurs in their 40's. The market to treat this condition is considerable. CustomVis has developed and is trialling a new multi-zone treatment for Presbyopia. To date, the treatment parameters have undergone three adjustments during the trials. The results from all treatments when analyzed together are extremely encouraging, with 95 per cent. of those treated being satisfied or extremely satisfied with their bilateral near and far vision. More importantly, the Directors consider the preliminary results from the test group after the last adjustment of parameters to be excellent. If these results continue, then there is likely to be a very large market opportunity for the Company.

#### REPRESENTATIONS AT TRADESHOWS AND CONFERENCES

The attendance at trade shows and conferences is an important element of the sale and marketing efforts, as it provides the opportunity to demonstrate the ease of use of the Pulzar Z1, allowing attendees a direct comparison between the quiet operation of the Solid State Pulzar Z1 against the very noticeable noise levels generated by excimer lasers, and to also allow potential customers to appreciate the small footprint and physical size of Pulzar Z1, its turnkey operation and its simplicity of use.

The Company continues to stimulate interest in the Pulzar Z1 product through attendance of relevant conferences as follows;

- The ESCRS (European Society of Cataract and Refractive Surgeons) held at EXCEL, London in September 2006.
- AAO (American Academy of Ophthalmology) in Las Vegas in November 2006
- AIOS (All India Ophthalmological Society) in Hyderabad, India in February 2007
- The ESCRS Winter Conference in Athens in February 2007
- APAO (Asia Pacific Academy of Ophthalmology) in Lahore, Pakistan in February 2007
- ARVO (The Association for Research in Vision and Ophthalmology) in Singapore in March 2007
- ASCRS (American Society of Cataract and Refractive Surgeons) in San Diego in April 2007
- IOA (Indonesian Ophthalmologist Association) in Jakarta in June 2007
- SFO (Societe Francaise d'Ophtalmologie) in Paris in May 2007
- 20th International Congress of German Ophthalmic Surgeons in May 2007
- MEACO - Middle East African Council of Ophthalmology in Dubai in March 2007

In the current year CustomVis intends to continue its strategy of exhibiting at trade conferences in order to demonstrate to the ophthalmic community the benefits and advantages of Solid State technology.

The Company recently attended the ESCRS (European Society of Cataract and Refractive Surgeons) Conference in Stockholm, Sweden and the AAO (American Academy of Ophthalmology) in New Orleans, and is scheduled to attend the following trade conferences between 1 November 2007 and 30 June 2008

- RANZCO (Royal Australian and New Zealand Conference of Ophthalmology) in Perth in November
- AIOS (All India Ophthalmological Society) in Bangalore, India in January 2008
- The ESCRS Winter Conference in Barcelona in February 2008
- ASCRS (American Society of Cataract and Refractive Surgeons) in Chicago in April 2008
- WOC (World Ophthalmic Congress) & APAO (Asia Pacific Academy of Ophthalmology) in Singapore in June 2008

Current Trading

Since 30 June 2007 the Company has signed firm sale contracts for ten lasers and is in the process of finalising sale contracts for another four lasers by end November 2007. The demand for the Company's product continues to be strong despite a highly competitive market place and the Directors are confident that they achieve the target of selling three lasers per month.

Summary

Overall the Company has made solid progress during the year ended 30 June 2007:

- Turnover has increased to £880,613 compared to £89,088 in 2006.
- Other operating income has increased to £328,307 compared to £166,246 in 2006.
- Loss per ordinary share on a diluted basis has reduced to 1.80p (2006: 3.89p)

The executive officers are to be congratulated on their continued strenuous efforts to develop the Pulsar Z1 laser to its current high performance levels and world wide sales. At the recent European Cataract & Refractive Surgeons conference in Sweden, there was a very active interest in the laser with evidence of serious intent to pursue purchases. The Company now looks forward to its next stage of development.

Emmanuel Rosen

Chairman

GROUP PROFIT AND LOSS ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2007

	Notes	Year ended 30 June 2007 £	As restated Year ended 30 June 2006 £
Turnover		880,613	89,088
Cost of sales		(482,917)	(32,318)
		-----	-----
Gross profit		397,696	56,770
Administrative expenses - Operational		(2,111,771)	(2,452,072)
- Share based payments		(107,860)	(3,543)
Other operating income		328,307	166,246
		-----	-----
Operating loss	2	(1,493,628)	(2,232,599)
Interest receivable and similar income	3	55,310	72,680
		-----	-----
Loss on ordinary activities before taxation		(1,438,318)	(2,159,919)
Tax on loss on ordinary activities	4	-	-
		-----	-----
Loss on ordinary activities after taxation transferred to reserves		(1,438,318)	(2,159,919)
		=====	=====
Loss per Ordinary Share			
Basic	5	(1.80)p	(3.89)p
		=====	=====
Diluted	5	(1.80)p	(3.89)p
		=====	=====

GROUP STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

FOR THE YEAR ENDED 30 JUNE 2007

Notes	Year ended 30 June 2007	Year ended 30 June 2006
-------	-------------------------------	-------------------------------

	2007	30 June
	£	2006
		£
Loss for the financial year	(1,438,318)	(2,159,919)
Currency translation differences on foreign currency net investments	(17,777)	(14,800)
	-----	-----
Total recognised gains and losses relating to the year	(1,456,095)	(2,174,719)
	=====	=====
Prior period adjustment	11 (309,155)	-----
	-----	-----
Total gains and losses recognised since last annual report	(1,765,250)	=====
	=====	=====

All the above figures relate to continuing activities.

#### GROUP BALANCE SHEET

AS AT 30 JUNE 2006

Notes	2007	As restated
	2006	2006
	£	£
Fixed assets		
Tangible assets	218,662	296,471
	-----	-----
	218,662	296,471
Current Assets		
Stock	1,117,917	945,589
Debtors (of which £401,666 (2006: £NIL) is due after more than one year)	6 923,481	71,382
Cash at bank and in hand	897,399	1,237,786
	-----	-----
	2,938,797	2,254,757
Creditors: amounts falling due within one year	7 (618,951)	(187,992)
	-----	-----
Net current assets	2,319,846	2,066,765
	-----	-----
Total assets less current liabilities	2,538,508	2,363,236
Creditors: amounts falling due after more than one year	7 (139,861)	-
	-----	-----
Net assets	2,398,647	2,363,236
	=====	=====
Capital and reserves		
Called up share capital	7 4,765,957	3,240,957
Share premium account	10,301,015	10,442,369
Option reserve	417,015	309,155
Foreign currency translation reserve	127,189	144,966
Profit and loss account	(13,212,529)	(11,774,211)
	-----	-----
Equity shareholders funds	2,398,647	2,363,236
	=====	=====

#### GROUP CASH FLOW STATEMENT

FOR THE YEAR ENDED 30 JUNE 2007

Notes	Year ended	As restated
	30 June	Year ended 30

	2007	2006
	£	£
Reconciliation of operating loss to net cash outflow from operating activities		
Operating loss	(1,493,628)	(2,232,599)
Depreciation and amortisation	2 134,580	100,493
Loss on sale of fixed assets	2 -	13,028
Share based payments	107,860	3,543
Increase in stock	(172,328)	(11,695)
(Increase)/decrease in debtors	(852,099)	107,233
Increase/(decrease) in creditors	570,820	(269,976)
Exchange rate differences arising on cash balances	(2,092)	2,618
	-----	-----
Net cash outflow from operating activities	(1,706,887)	(2,287,355)
	=====	=====
Cash Flow Statement		
Net cash outflow from operating activities	(1,706,887)	(2,287,355)
Return on investments and servicing of finance	9 55,310	72,680
Capital expenditure	9 (72,456)	3,260
	-----	-----
Financing	(1,724,033)	(2,211,415)
	9 1,383,646	1,484,203
	-----	-----
Decrease in cash in the year	10 (340,387)	(727,212)
	=====	=====
Reconciliation of net cash flow to movement in net funds		
Decrease in cash in the year	(340,387)	(727,212)
Net funds at 30 June 2006	1,237,786	1,964,998
	-----	-----
Net funds at 30 June 2007	897,399	1,237,786
	=====	=====

## NOTES TO THE FINANCIAL STATEMENTS

### FOR THE YEAR ENDED 30 JUNE 2007

#### 1. ACCOUNTING POLICIES

##### 1.1 Fundamental accounting concept and basis of preparation of financial statements

At the balance sheet date the Group had £0.90 million of cash, £0.76 million of creditors (of which £0.62 million are due within one year) and no long term debt.

The Directors are encouraged by the sales made during 2006/07 and by the further sales made since the balance sheet date. The directors have prepared financial projections for the period beyond twelve months from the date of signing these financial statements. Based on the projected income to be generated from future sales and including a cost management programme the directors are pursuing, the directors believe that the going concern basis continues to be appropriate.

In addition to the points noted above the Director's are also pursuing a number of additional funding options and are currently in discussions with several parties.

Whilst the Company has historically not met its financial projections the Directors have reviewed the current forward projections and are confident that they are achievable.

The financial statements are prepared under the historical cost convention. The Group has consistently applied all relevant accounting standards, except that Financial Reporting Standard Number 20 - Share -based payment ("FRS 20") has been adopted for the first time this year.

The Auditors' Report to the financial statements for the year ended 30 June 2007 includes the following:

"Emphasis of matter - Going concern

In forming our opinion, which is not qualified, we have considered the adequacy of the disclosure made in note 1.1 to the financial statements concerning the company and group's ability to continue as a going concern. The Group incurred a net loss of £1.44 million for the year ended 30 June 2007 and at that date its net assets totalled £ 2.40 million. As explained in note 1.1 for the Group to continue as a going concern it is dependent on income from future sales. The projections prepared by the directors include assumptions on the timing and amounts of such future sales which indicate the existence of a material uncertainty which may cast significant doubt on the company and the group's ability to continue as a going concern. The financial statements do not include the adjustments that would result if the Company and Group was unable to continue as a going concern. "

1.3 Basis of Consolidation

The Group financial statements consolidate the financial statements of CustomVis plc and its subsidiary undertaking up to 30 June 2007. No profit and loss account is presented for CustomVis plc as permitted by section 230 of the Companies Act 1985. CLVR Pty. Ltd has been included in the Group financial statements using the acquisition method of accounting. Accordingly, the primary financial statements include the results and cash flows of CLVR Pty. Ltd. for the year. The loss incurred by the parent Company for the year ended 30 June 2007 was £2,780,295 (2006 - loss of £846,018 (as restated)).

2. OPERATING LOSS

	2007	2006
	£	£
Operating loss is stated after charging:		
Depreciation	134,580	100,493
Operating lease payments - land and buildings	144,805	136,497
Foreign exchange (gains )/losses	(18,380)	36,994
Share based payments	107,860	3,543
Loss on disposal of fixed assets	-	13,028
Research and development	29,213	9,617
expenditure in current year		
Auditors' remuneration (detailed below)	7,068	5,970
Fees payable to the company's auditor for the audit of the company's annual accounts		
Fees payable to the company's auditor and its associates in respect of :		
-The auditing of accounts of associates of the company pursuant to legislation (including that of countries and territories outside Great Britain)	24,755	15,119
-Services supplied pursuant to such legislation	1,543	3,387
-Services relating to taxation	2,644	9,285
-Services relating to corporate finance transactions entered into or proposed to be entered into by or on behalf		

entered into or proposed to be entered into by or on behalf

of the company or any of its associates 7,500 -

-All other services 9,096 8,278

=====

and after crediting:  
Government grants

259,605 52,056

=====

3. INTEREST RECEIVABLE AND SIMILAR INCOME

2007 2006  
£ £

Bank interest 55,310 72,680  
=====

4. TAX ON LOSS ON ORDINARY ACTIVITIES

2007 2006

£ £

Current Tax

Overseas taxation - -  
-----

Factors affecting tax charge for the year

Loss on ordinary activities before tax (1,438,318) (2,159,919)  
-----

Loss on ordinary activities multiplied by the  
standard rate of corporation tax in the UK of 30  
per cent. (431,495) (647,976)  
Losses not utilised 396,635 641,872  
Expenses not deductible for tax purposes 34,860 6,104  
-----  
- -  
=====

Deferred taxation

The Group has losses carried forward estimated at £12,586,666 (2006 -  
£11,266,666) that give rise to a deferred taxation asset. This asset has not  
been incorporated into the financial statements as it is not certain at the  
balance sheet date that profits in the foreseeable future will be sufficient to  
allow this balance to be utilised.

5. LOSS PER SHARE

2007 2006  
£ £

Loss for the year attributable to shareholders (1,438,318) (2,159,919)  
=====

Weighted average number of shares in issue 80,069,148 55,582,984  
=====

The weighted average number of shares in issue for the year ended 30 June 2007  
was calculated by taking into account the additional 30,500,000 ordinary shares  
issued in January 2007.

Diluted loss per share has been calculated using the same figures as the basic  
calculation. No account has been taken of options, as these potential ordinary  
shares are not considered to be dilutive under the definitions of the applicable  
accounting standards.

## 6.1 TANGIBLE FIXED ASSETS

	Plant & Machinery	Fixtures, fittings & equipment	Leasehold Improvements	Leased Assets	Total
	£	£	£	£	£
Cost					
At 1 July 2006	305,244	150,211	19,234	108,299	582,988
Exchange differences	1,386	828	-	-	2,214
Additions	6,104	3,510	-	62,842	72,456
At 30 June 2007	312,734	154,549	19,234	171,141	657,658
Depreciation					
At 1 July 2006	160,982	100,476	6,571	18,488	286,517
Exchange differences	12,322	9,745	1,027	(5,195)	17,899
Charge for the year	42,059	34,296	3,948	54,277	134,580
At 30 June 2007	215,363	144,517	11,546	67,570	438,996
Net book value					
At 30 June 2006	144,262	49,735	12,663	89,811	296,471
At 30 June 2007	97,371	10,032	7,688	103,571	218,662

## 7. DEBTORS

	2007 £	2006 £
Due within one year		
Trade debtors	435,397	18,716
Other debtors	86,418	52,666
	521,815	71,382
Due after more than one year		
Trade debtors	401,666	-
	923,481	71,382

## 8. CREDITORS

	2007 £	2006 £
Amounts falling due within one year		
Trade creditors	335,743	154,226
Directors' account	20,398	16,537
Other creditors	155,784	15,266
Accruals and deferred income	107,026	1,963
	618,951	187,992
Amounts falling due after more than one year	139,861	-
Accruals and deferred income	139,861	-

## 9. POST BALANCE SHEET EVENTS

Subsequent to the year end the company has entered into contracts for the sale of 10 lasers with payments spread over terms ranging from two to three years.

## 10. GROSS CASH FLOWS

2007 £	2006 £
-----------	-----------

Returns on investments and servicing of finance		
Interest received	55,310	72,680
	=====	=====
Capital expenditure		
Proceeds from sale of tangible fixed assets	-	7,992
Payments to acquire tangible fixed assets	(72,456)	(4,732)
	-----	-----
	(72,456)	(3,260)
	=====	=====
Financing		
Issue of ordinary share capital (net of issue expenses)	1,383,646	1,484,203
	=====	=====

#### 11. ANALYSIS OF CHANGES IN NET FUNDS

Gross cash flows - Group	23. Gross cash flows - Group	Opening Balance	Cash Flows	Closing Balance
		£	£	£
Cash at bank and in hand		1,237,786	(340,387)	897,399
		=====	=====	=====

#### 12. PRIOR PERIOD ADJUSTMENT

The Company is required to adopt the provisions of Financial Reporting Standard 20: Share-based payments, which has given rise to a charge in the profit and loss account in the current year and prior year and a prior period adjustment in respect of preceding years.

The impact of this adjustment in the current year has been to reduce the profit and loss reserve by £107,860 and to increase the share option reserve by the same amount. The loss for the year has been increased by £107,860.

In respect of the prior period the profit and loss reserve has been reduced by £3,543, the share option reserve has been increased by £3,543 and the loss for the year increased by £3,543.

Amounts arising in respect of periods ended prior to the year ended 30 June 2006 have reduced the profit and loss reserve by £305,612 and given rise to a share option reserve of £305,612 at 30 June 2005.

#### 13. DIVIDENDS

No dividends were paid or proposed in respect of the year ended 30 June 2007.

#### 14. COPIES OF ACCOUNTS

A copy of the Annual Report and Accounts will be sent to all shareholders shortly and will be available from the Company's registered office, Ground Floor, 110 Erindale Road, Balcatta, Perth, Western Australia, 6021 Australia and from the Company's website [www.customvis.com](http://www.customvis.com)

-ends-